Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
PR Newswire —
SAN CARLOS, Calif., Jan. 6, 2026 /PRNewswire/ -- Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the advancement of its matrix metalloproteinase-9 (MMP9) antisense oligonucleotide (ASO) program,...